Education
About Us
Working with TipRanks
Follow Us
Rigel Pharmaceuticals (RIGL)
NASDAQ:RIGL
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 179.28M | $ 116.88M | $ 120.24M | $ 149.24M | $ 108.62M |
| Gross Profit | $ 160.63M | $ 109.77M | $ 118.49M | $ 148.15M | $ 107.73M |
| Operating Income | $ 24.19M | $ -20.49M | $ -55.55M | $ -12.50M | $ -28.97M |
| EBITDA | $ 28.51M | $ -16.98M | $ -53.87M | $ -11.29M | $ -27.68M |
| Net Income | $ 17.48M | $ -25.09M | $ -58.57M | $ -17.91M | $ -29.74M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 77.32M | $ 56.93M | $ 58.21M | $ 124.97M | $ 57.33M |
| Total Assets | $ 163.98M | $ 117.22M | $ 134.28M | $ 167.33M | $ 110.38M |
| Total Debt | $ 59.97M | $ 60.58M | $ 41.55M | $ 30.57M | $ 39.09M |
| Net Debt | $ 3.22M | $ 27.79M | $ 17.09M | $ 11.68M | $ 8.71M |
| Total Liabilities | $ 160.69M | $ 145.87M | $ 147.90M | $ 136.95M | $ 76.35M |
| Stockholders' Equity | $ 3.29M | $ -28.64M | $ -13.62M | $ 30.37M | $ 34.03M |
| Cash Flow | |||||
| Free Cash Flow | $ 31.07M | $ -20.74M | $ -74.21M | $ 5.25M | $ -53.45M |
| Operating Cash Flow | $ 31.47M | $ -5.74M | $ -73.76M | $ 5.88M | $ -52.19M |
| Investing Cash Flow | $ 4.13M | $ -4.30M | $ 72.78M | $ -80.04M | $ 47.47M |
| Financing Cash Flow | $ -11.64M | $ 18.37M | $ 6.55M | $ 62.67M | $ 12.57M |
Rigel Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.